Cameron Buttermore is a senior associate in Goodwin’s Business Law department and a member of its Technology and Life Sciences practice group. Cameron represents high-growth life sciences, biotechnology, medical device and technology companies on a wide range of business and legal issues throughout the corporate lifecycle. Cameron also advises venture capital and growth equity firms on their portfolio company investments and acquisitions in the Technology and Life Sciences industries.
Cameron works closely with clients’ management teams and boards of directors on corporate governance and strategic matters, including general corporate law matters, startup and emerging growth company issues, personnel matters and corporate development strategies. In addition to day-to-day corporate counseling and strategic advice to clients, Cameron advises on a variety of major business transactions, including venture capital financings, M&A transactions and strategic transactions.
Experience
A selection of Cameron’s client representations include:
- ARKUDA Therapeutics in its $64 million Series B financing
- AsclepiX Therapeutics in its $10 million Series A-3 financing
- Clarametyx Biosciences in its $33 million Series A financing
- DROIA Ventures in connection with its investment in the Series A financing of Actio Biosciences
- Garuda Therapeutics in its $62 million Series B financing
- HLM Venture Partners in its investment in HealthEC
- IDRX in its $122 million Series A financing
- IDRX in its $120 million Series B financing
- Insight Partners in connection with its investment in the Series Seed financing of Capacity Bio
- MBX Biosciences in its $115 million Series B financing
- MBX Biosciences in its $63.5 million Series C financing
- Revelation Partners in its investment in the $147.5 million Series B financing of Aspen Neuroscience
- Septerna in its $150 million Series B financing
- Upstream Bio in its $200 million Series B financing
- Akston Biosciences in the sale of certain insulin programs to Dechra Limited for an undisclosed purchase price
- Biocon Biologics in its $3.335 billion acquisition of the global biosimilars business of Viatris Inc. (NASDAQ: VTRS)
- Deerfield Catalyst, a medtech incubator committed to developing transformational solutions to improve patient outcomes and streamline care, in its formation, structuring and funding matters and spinout transactions
- KBP Biosciences in the sale to Novo Nordisk of ocedurenone, a drug for uncontrolled hypertension with potential application in cardiovascular and kidney disease, for up to $1.3 billion
- Galecto in its $50 million “at-the-market” offering
- Karuna Therapeutics in its $460 million underwritten public offering
- Rocket Pharmaceuticals in its $200 million “at-the-market” offering
- TScan Therapeutics in its $140.7 million underwritten public offering
Professional Experience
Prior to joining Goodwin, Cameron was an associate at Troutman Pepper Hamilton Sanders LLP.
Credentials
Education
JD2019
Drexel University School of Law
BA2016
Colgate University
Admissions
Bars
- New York
- Florida